Ocugen (OCGN) EGM 2026 summary
Event summary combining transcript, slides, and related documents.
EGM 2026 summary
28 Sep, 2026Opening remarks and agenda
Meeting called to order and held virtually to maximize stockholder participation.
Introduction of board members and management present at the meeting.
Agenda and rules of conduct established and made available to participants.
Specific resolutions to be voted on
Proposal to amend the Charter to increase authorized common stock by 250 million shares.
Proposal to approve adjournment of the meeting to solicit additional proxies if needed.
Corporate governance
Quorum established with at least one-third of voting power represented.
Voting rights and procedures clarified, including proxy voting and record date.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Ocugen
- OCU400’s Q1 2027 readout anchors a broad, late-stage gene-therapy pipeline.OCGN
Stifel 2026 Healthcare Conference 2026 - Virtual special meeting set for Dec. 22; voting closes Dec. 21.OCGN
Proxy filing - Board backs a 250 million-share authorization increase for the December 22 vote.OCGN
Proxy filing - 2027 pivotal readouts approach amid going-concern and share-conversion risks.OCGN
Q3 2026 - The 250 million-share authorization vote was deferred to October 26.OCGN
EGM 2026 - Late-stage gene therapies for major eye diseases advance toward BLA filings, with cash runway into 2028.OCGN
H.C. Wainwright 28th Annual Global Investment Conference - Shareholders will vote to increase authorized shares to support growth and commercialization.OCGN
Proxy filing - Pivotal gene therapy trials for RP and Stargardt aim for global launches by 2028.OCGN
Canaccord Genuity's 46th Annual Growth Conference - FDA cleared OCU410 phase III; $130M financing extends cash runway to 2028 amid going concern risk.OCGN
Q2 2026